|
|
||||||||
Papers In Press, published online ahead of print November 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 44, 2109-2119, November 2003
Copyright © 2003 by American Society for Biochemistry and Molecular Biology
Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, 1230 York Avenue, Box 179, New York, NY 10021
1 To whom correspondence should be addressed. e-mail: breslow{at}rockefeller.edu
High-cholesterol diets elicit changes in gene expression via such transcription factors as sterol-regulatory element binding proteins (SREBPs) and liver X receptors (LXRs). We used Affymetrix microarrays to identify genes in mouse liver regulated by dietary cholesterol (0.0% vs. 0.5% cholesterol wt/wt). Three independent experiments were performed, and data were analyzed with Affymetrix Microarray Suite and ANOVA statistical software. There were 69 unique Unigene clusters consistently regulated by dietary cholesterol (37 downregulated and 32 upregulated). The array results were confirmed by quantitative RT-PCR (Q-PCR) for seven of nine downregulated genes and five of six upregulated genes. A time course of dietary cholesterol feeding over 1 week revealed different temporal patterns of gene regulation for these confirmed genes. Six downregulated genes were examined in transgenic mice overexpressing truncated nuclear forms of SREBP-1a and SREBP-2, and all were induced in these mice. A second microarray analysis of mice treated with the LXR agonist TO901317 confirmed that 13 of the 32 cholesterol upregulated genes were also LXR-activated. This array result was confirmed by Q-PCR for three of three genes.
In summary, these studies identified and confirmed six novel dietary cholesterol-regulated genes, three putative SREBP target genes (calcium/calmodulin-dependent protein kinase 1D, fatty acid binding protein 5, and proprotein convertase subtilisin/kexin 9), and three putative LXR target genes (a disintegrin and metalloprotease domain 11, apoptosis-inhibitory 6, and F-box-only protein 3).
Abbreviations: Abcg5, ATP binding cassette, subfamily G, member 5; Acac, acetyl-CoA carboxylase; Acly, ATP citrate lyase; Adam11, a disintegrin and metalloprotease domain 11; Api6, apoptosis-inhibitory 6; Camk1D, calcium/calmodulin-dependent protein kinase 1D; CYP7A1, cholesterol 7-
-hydroxylase; FABP5, fatty acid binding protein 5; Fbxo3, F-box-only protein 3; HMGCR, HMG-CoA reductase; HMGCS, HMG-CoA synthase; Laptm5, lysosomal-associated protein transmembrane 5; LXR, liver X receptor; Pcsk9, proprotein convertase subtilisin/kexin 9; Rgs16, regulator of G-protein signaling 16; SAA3, serum amyloid A 3; Sqle, squalene epoxidase; SREBP, sterol-regulatory element binding protein; StarD4, StAR-related lipid transfer domain containing 4
Supplementary key words dietary cholesterol oligonucleotide arrays gene expression profiling sterol-regulatory element binding proteins liver X receptor
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D.-W. Zhang, R. Garuti, W.-J. Tang, J. C. Cohen, and H. H. Hobbs Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor PNAS, September 2, 2008; 105(35): 13045 - 13050. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Madsen, R. K. Petersen, K. R. Steffensen, L. M. Pedersen, P. Hallenborg, T. Ma, L. Froyland, S. O. Doskeland, J.-A. Gustafsson, and K. Kristiansen Activation of Liver X Receptors Prevents Statin-induced Death of 3T3-L1 Preadipocytes J. Biol. Chem., August 15, 2008; 283(33): 22723 - 22736. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Steinberg, C. K. Glass, and J. L. Witztum Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia Circulation, August 5, 2008; 118(6): 672 - 677. [Full Text] [PDF] |
||||
![]() |
A. S. Peterson, L. G. Fong, and S. G. Young Errata. PCSK9 function and physiology J. Lipid Res., July 1, 2008; 49(7): 1595 - 1599. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Peterson, L. G. Fong, and S. G. Young PCSK9 function and physiology J. Lipid Res., June 1, 2008; 49(6): 1152 - 1156. [Full Text] [PDF] |
||||
![]() |
W. S. Garver, D. Jelinek, G. A. Francis, and B. D. Murphy The Niemann-Pick C1 gene is downregulated by feedback inhibition of the SREBP pathway in human fibroblasts J. Lipid Res., May 1, 2008; 49(5): 1090 - 1102. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kourimate, C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zair, P. Nguyen, M. Krempf, B. Cariou, and P. Costet Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9 J. Biol. Chem., April 11, 2008; 283(15): 9666 - 9673. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Jeong, H.-S. Lee, K.-S. Kim, Y.-K. Kim, D. Yoon, and S. W. Park Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2 J. Lipid Res., February 1, 2008; 49(2): 399 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Newberry, S. M. Kennedy, Y. Xie, B. T. Sternard, J. Luo, and N. O. Davidson Diet-induced obesity and hepatic steatosis in L-Fabp / mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G307 - G314. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Fisher, P. L. Surdo, S. Pandit, M. Mattu, J. C. Santoro, D. Wisniewski, R. T. Cummings, A. Calzetta, R. M. Cubbon, P. A. Fischer, et al. Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation J. Biol. Chem., July 13, 2007; 282(28): 20502 - 20512. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Benjannet, D. Rhainds, J. Hamelin, N. Nassoury, and N. G. Seidah The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A: FUNCTIONAL CONSEQUENCES OF NATURAL MUTATIONS AND POST-TRANSLATIONAL MODIFICATIONS J. Biol. Chem., October 13, 2006; 281(41): 30561 - 30572. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hoekstra, M. Stitzinger, E. J. A. van Wanrooij, I. N. Michon, J. K. Kruijt, J. Kamphorst, M. Van Eck, E. Vreugdenhil, T. J. C. Van Berkel, and J. Kuiper Microarray analysis indicates an important role for FABP5 and putative novel FABPs on a Western-type diet J. Lipid Res., October 1, 2006; 47(10): 2198 - 2207. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lambert, A.-L. Jarnoux, T. Pineau, O. Pape, M. Chetiveaux, C. Laboisse, M. Krempf, and P. Costet Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor Endocrinology, October 1, 2006; 147(10): 4985 - 4995. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Ratliff, A. Gutierrez, and R. A. Davis Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia J. Lipid Res., July 1, 2006; 47(7): 1513 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cameron, O. L. Holla, T. Ranheim, M. A. Kulseth, K. E. Berge, and T. P. Leren Effect of mutations in the PCSK9 gene on the cell surface LDL receptors Hum. Mol. Genet., May 1, 2006; 15(9): 1551 - 1558. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Berge, L. Ose, and T. P. Leren Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1094 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Costet, B. Cariou, G. Lambert, F. Lalanne, B. Lardeux, A.-L. Jarnoux, A. Grefhorst, B. Staels, and M. Krempf Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c J. Biol. Chem., March 10, 2006; 281(10): 6211 - 6218. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Getz and C. A. Reardon Diet and Murine Atherosclerosis Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 242 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. van Erpecum, D. Q-H. Wang, A. Moschetta, D. Ferri, M. Svelto, P. Portincasa, J.-J. Hendrickx, M. Schipper, and G. Calamita Gallbladder histopathology during murine gallstone formation: relation to motility and concentrating function J. Lipid Res., January 1, 2006; 47(1): 32 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Curtiss, D. T. Valenta, N. J. Hime, and K.-A. Rye What Is So Special About Apolipoprotein AI in Reverse Cholesterol Transport? Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 12 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Naoumova, I. Tosi, D. Patel, C. Neuwirth, S. D. Horswell, A. D. Marais, C. van Heyningen, and A. K. Soutar Severe Hypercholesterolemia in Four British Families With the D374Y Mutation in the PCSK9 Gene: Long-Term Follow-Up and Treatment Response Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2654 - 2660. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lalanne, G. Lambert, M. J. A. Amar, M. Chetiveaux, Y. Zair, A.-L. Jarnoux, K. Ouguerram, J. Friburg, N. G. Seidah, H. B. Brewer Jr., et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells J. Lipid Res., June 1, 2005; 46(6): 1312 - 1319. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Cunningham, D. Swartzlander, S. Liyanarachchi, R. V. Davuluri, and G. E. Herman Changes in gene expression associated with loss of function of the NSDHL sterol dehydrogenase in mouse embryonic fibroblasts J. Lipid Res., June 1, 2005; 46(6): 1150 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Soccio, R. M. Adams, K. N. Maxwell, and J. L. Breslow Differential Gene Regulation of StarD4 and StarD5 Cholesterol Transfer Proteins: ACTIVATION OF StarD4 BY STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 AND StarD5 BY ENDOPLASMIC RETICULUM STRESS J. Biol. Chem., May 13, 2005; 280(19): 19410 - 19418. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-M. Sun, E. R. Eden, I. Tosi, C. K. Neuwirth, D. Wile, R. P. Naoumova, and A. K. Soutar Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia Hum. Mol. Genet., May 1, 2005; 14(9): 1161 - 1169. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rashid, D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y.-A. Moon, and J. D. Horton Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 PNAS, April 12, 2005; 102(15): 5374 - 5379. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Maxwell, E. A. Fisher, and J. L. Breslow Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment PNAS, February 8, 2005; 102(6): 2069 - 2074. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Morgan, Z. Jayyosi, M. A. Hower, M. V. Pino, T. M. Connolly, K. Kotlenga, J. Lin, M. Wang, H.-L. Schmidts, M. S. Bonnefoi, et al. The Hepatic Transcriptome as a Window on Whole-Body Physiology and Pathophysiology Toxicol Pathol, January 1, 2005; 33(1): 136 - 145. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Valledor, L.-C. Hsu, S. Ogawa, D. Sawka-Verhelle, M. Karin, and C. K. Glass Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis PNAS, December 21, 2004; 101(51): 17813 - 17818. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Benjannet, D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M.-C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. NARC-1/PCSK9 and Its Natural Mutants: ZYMOGEN CLEAVAGE AND EFFECTS ON THE LOW DENSITY LIPOPROTEIN (LDL) RECEPTOR AND LDL CHOLESTEROL J. Biol. Chem., November 19, 2004; 279(47): 48865 - 48875. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. E. Richards, B. Chau, M. R. White, and C. A. McQueen Hepatic Gene Expression and Lipid Homeostasis in C57Bl/6 Mice Exposed to Hydrazine or Acetylhydrazine Toxicol. Sci., November 1, 2004; 82(1): 318 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, P. Gargalovic, J. Wong, J. L. Gu, X. Wu, H. Qi, P. Wen, L. Xi, B. Tan, R. Gogliotti, et al. Hyplip2, a New Gene for Combined Hyperlipidemia and Increased Atherosclerosis Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1928 - 1934. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Jirholt, M. Adiels, and J. Boren How Does Mutant Proprotein Convertase Neural Apoptosis-Regulated Convertase 1 Induce Autosomal Dominant Hypercholesterolemia? Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1334 - 1336. [Full Text] [PDF] |
||||
![]() |
A. D. Attie The Mystery of PCSK9 Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1337 - 1339. [Full Text] [PDF] |
||||
![]() |
G. Dubuc, A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, and A. Prat Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1454 - 1459. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Maxwell and J. L. Breslow Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype PNAS, May 4, 2004; 101(18): 7100 - 7105. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Frederiksen, E. M. Wulff, P. Sauerberg, J. P. Mogensen, L. Jeppesen, and J. Fleckner Prediction of PPAR-{alpha} ligand-mediated physiological changes using gene expression profiles J. Lipid Res., March 1, 2004; 45(3): 592 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tiemann, Z. Han, R. Soccio, J. Bollineni, S. Shefer, E. Sehayek, and J. L. Breslow Cholesterol feeding of mice expressing cholesterol 7{alpha}-hydroxylase increases bile acid pool size despite decreased enzyme activity PNAS, February 17, 2004; 101(7): 1846 - 1851. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |